Opinion|Videos|September 9, 2024
Treatment Guidelines for C. difficile Infection
Experts on C. difficile infections give an overview of the ACG and IDSA/SHEA treatment guidelines for initial infection, first recurrence, and subsequent recurrences.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What is the recommended treatment for initial CDI, first recurrence, and subsequent recurrences?
Advertisement
Related to this article
In an ECOSPOR III analysis, all-cause hospitalization by week 4 fell to 3.4% with fecal microbiota spores vs 16.1% with placebo in recurrent C difficile infection.
In the phase 2 RePreve trial, Lumen Bioscience’s investigational oral biologic LMN-201 plus standard antibiotics achieved global cure in 83.3% of patients with C difficile infection vs 36.4% with placebo, and cut recurrence sixfold (9.1% vs 55.6%) with no drug-related serious adverse events.
Advertisement
Advertisement
Trending on Contagion Live
1
Cefiderocol-Xeruborbactam Active Against Carbapenem-Resistant Bacteria
2
Pritelivir Cuts Hospital Days in Refractory HSV in Phase 3 PRIOH-1
3
Zelicapavir Shortens RSV Symptoms Despite Missing Primary End Point
4
Ensitrelvir PEP Eases Symptom Severity in COVID-19 Breakthrough Cases
5